Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Cash (2020 - 2025)

Historic Change in Cash for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$22.4 million.

  • Relay Therapeutics' Change in Cash fell 22682.5% to -$22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.7 million, marking a year-over-year decrease of 1385374.15%. This contributed to the annual value of -$20.0 million for FY2024, which is 15270.53% down from last year.
  • As of Q3 2025, Relay Therapeutics' Change in Cash stood at -$22.4 million, which was down 22682.5% from $20.5 million recorded in Q2 2025.
  • Over the past 5 years, Relay Therapeutics' Change in Cash peaked at $246.9 million during Q3 2022, and registered a low of -$202.8 million during Q4 2022.
  • For the 5-year period, Relay Therapeutics' Change in Cash averaged around -$18.7 million, with its median value being -$11.7 million (2022).
  • Examining YoY changes over the last 5 years, Relay Therapeutics' Change in Cash showed a top increase of 88358.3% in 2022 and a maximum decrease of 113123.03% in 2022.
  • Quarter analysis of 5 years shows Relay Therapeutics' Change in Cash stood at $51.6 million in 2021, then plummeted by 493.42% to -$202.8 million in 2022, then skyrocketed by 96.26% to -$7.6 million in 2023, then crashed by 269.73% to -$28.1 million in 2024, then grew by 20.28% to -$22.4 million in 2025.
  • Its Change in Cash was -$22.4 million in Q3 2025, compared to $20.5 million in Q2 2025 and -$30.7 million in Q1 2025.